Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
NEW YORK, March 16, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Horizon Pharma plc (NASDAQ:HZNP) securities between March 13, 2014 and February 26, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/horizon-pharma. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Horizon’s Prescriptions Made Easy (“PME”) program was designed to artificially inflate the prices of minor differentiation standard retail drugs; (ii) sales revenues from drugs sold through Horizon’s PME program were unsustainable at these inflated price levels; and (iii) Horizon’s use of its PME program left the Company subject to increased regulatory risks.
On February 29, 2016, Horizon disclosed in its 2015 annual report that the Company received a subpoena in November 2015 from the Office of the U.S. Attorney for the Southern District of New York for documents and information related to the Company’s patient assistance programs and other aspects of Horizon’s sales and marketing activities.
If you suffered a loss in Horizon you have until May 9, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/horizon-pharma.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigation involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
